Latest Clinical Trials
Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition University of Pennsylvania NA
WITHDRAWN
(Sep 1, 2026)
PHASE3 Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS Zealand Pharma NA
COMPLETED
(Sep 1, 2026)
PHASE3 Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes Universitaire Ziekenhuizen KU Leuven NA
RECRUITING
(Sep 1, 2026)
PHASE3 Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes Victor Chang Cardiac Research Institute NA
RECRUITING
(Sep 1, 2026)
PHASE2 A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes Hoffmann-La Roche NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes Hoffmann-La Roche NA
RECRUITING
(Sep 1, 2026)
PHASE3 Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease The Methodist Hospital Research Institute NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes Hoffmann-La Roche NA
RECRUITING
(Sep 1, 2026)
PHASE3 Supplementation of Gut-brain Axis (GLP-1)-Activating Carbohydrates for Increasing Satiety in Adolescents With Obesity Indiana University NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 Semaglutide Therapy for Alcohol Reduction (STAR) National Institute on Drug Abuse (NIDA) NA
ACTIVE NOT RECRUITING
(Aug 31, 2026)
PHASE2 Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes AdventHealth Translational Research Institute NA
RECRUITING
(Aug 1, 2026)
PHASE2 Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome University of Colorado, Denver NA
RECRUITING
(Aug 1, 2026)
PHASE3 Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome Beni-Suef University NA
COMPLETED
(Aug 1, 2026)
PHASE3 GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial Vanderbilt University Medical Center NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2, PHASE3 Avexitide for Treatment of Post-Bariatric Hypoglycemia Amylyx Pharmaceuticals Inc. NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Dorzagliatin in Pancreatic Insufficient Cystic Fibrosis Michael R. Rickels, MD, MS NA
RECRUITING
(Aug 1, 2026)
PHASE1 Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial City of Hope Medical Center NA
RECRUITING
(Aug 1, 2026)
PHASE2 Studies of Insulin and Glucagon Action in the Liver Duke University NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer National Cancer Institute (NCI) NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes Mellitus Mapi Pharma Ltd. NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF) VectivBio AG NA
RECRUITING
(Aug 1, 2026)
PHASE3 A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/Obesity Chia Tai Tianqing Pharmaceutical Group Co., Ltd. NA
RECRUITING
(Aug 1, 2026)
PHASE1 Impact of GLP-1 Receptor Agonist Therapy on Alcohol Pharmacokinetics University of Wisconsin, Madison NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE1 A Clinical Trial of TQF3250 Capsules in Overweight/Obese Trial Participants With Poor Weight Control Through Simple Lifestyle Intervention Chia Tai Tianqing Pharmaceutical Group Co., Ltd. NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE1 An Exploratory Study of Single-Dose and Multiple-Doses IBI3042 in Healthy, Overweight, or Obese Participants Hongwei Jiang NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE1 Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD) National Institute on Alcohol Abuse and Alcoholism (NIAAA) NA
RECRUITING
(Jul 22, 2026)
PHASE1 Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism Zealand Pharma NA
COMPLETED
(Jul 1, 2026)
PHASE3 Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM University of California, San Diego NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) Novo Nordisk A/S NA
RECRUITING
(Jul 1, 2026)
PHASE1 CLF065 for Chronic Pouchitis Calibr, a division of Scripps Research NA
SUSPENDED
(Jul 1, 2026)
PHASE2 Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes Emory University NA
RECRUITING
(Jul 1, 2026)
PHASE3 Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME) West China Hospital NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2, PHASE3 Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial yifang zhu NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2, PHASE3 Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity Shahid Beheshti University of Medical Sciences NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE3 GLP-1 Agonists for Lung Function Improvement and Muscle Restoration in COPD The Cleveland Clinic NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 Lifestyle Counseling and Medication for Adolescent Weight Management University of Minnesota NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD) Chinese University of Hong Kong NA
RECRUITING
(Jun 1, 2026)
PHASE2 Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese Eli Lilly and Company NA
COMPLETED
(Jun 1, 2026)
PHASE2 Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes University of California, San Diego NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure Jens D Hove, MD,PHD NA
RECRUITING
(Jun 1, 2026)
PHASE2, PHASE3 Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity University of Colorado, Denver NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE3 Semaglutide (Wegovy) Treatment for Trichotillomania University of Chicago NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events Novo Nordisk A/S NA
RECRUITING
(Jun 1, 2026)
PHASE1 Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy Vanderbilt University Medical Center NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Discontinuation One Week Recommendations for GLP-1 Receptor Agonists Prior to Esophagogastroduodenoscopy. Fu Jen Catholic University Hospital NA
RECRUITING
(Jun 1, 2026)
PHASE3 GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance University of Pennsylvania NA
RECRUITING
(May 1, 2026)
PHASE2 The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction Adrian Vella NA
RECRUITING
(May 1, 2026)
PHASE2 Effect of Aqueous Extracts of Cissus Quadrangularis and Dichrostachys Glomerata on GLP-1 Concentration and DPP-4 Activity in Overweight and Obese Adults University of Yaounde 1 NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Semaglutide for Smoking Cessation in Patients With Diabetes Ottawa Heart Institute Research Corporation NA
RECRUITING
(May 1, 2026)
PHASE3 The Role of Glucagon in Glucose Metabolism in Humans With and Without Bariatric Surgery The University of Texas Health Science Center at San Antonio NA
RECRUITING
(May 1, 2026)
PHASE1 GLP-1 Receptor Agonist in Primary Intracerebral Hemorrhage: A Phase 2 Randomized Trial Chinese University of Hong Kong NA
NOT YET RECRUITING
(May 1, 2026)
PHASE2 SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes. Ministry of Health, Saudi Arabia NA
NOT YET RECRUITING
(May 1, 2026)
PHASE2 The Effects of Glucagon on Hepatic Metabolism Adrian Vella NA
COMPLETED
(Apr 1, 2026)
PHASE1, PHASE2 A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes Zucara Therapeutics Inc. NA
RECRUITING
(Apr 1, 2026)
PHASE2 A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH Neuraly, Inc. NA
COMPLETED
(Apr 1, 2026)
PHASE2 Tailoring Obesity Treatment Trial Esbjerg Hospital - University Hospital of Southern Denmark NA
WITHDRAWN
(Apr 1, 2026)
PHASE2, PHASE3 A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia University of Florida NA
RECRUITING
(Apr 1, 2026)
PHASE2 The Role of Phosphodiesterase Inhibitors in Incretin Secretion National Institute on Aging (NIA) NA
COMPLETED
(Mar 11, 2026)
PHASE1 To Determine Tolerability to Glucagon Infusion in Obese Subjects AdventHealth Translational Research Institute NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE1 Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia Fudan University NA
COMPLETED
(Mar 1, 2026)
PHASE2, PHASE3 Repurposing Semaglutide for the Treatment of Cocaine Use Disorder The University of Texas Health Science Center, Houston NA
RECRUITING
(Mar 1, 2026)
PHASE2 
